Learn more about the exciting lead products of ImmunoClin.
Multi-Variant Atherosclerosis Risk Assessment (MARA™)
Cardiovascular disease involves a complex interplay of cells and signalling molecules. MARA™ is an intelligent algorithm to analyze the complex multi-variant data (cytokines and cellular markers) to identify people who are at risk of having heart attack. MARA™ detects inflammatory factors that contribute to causing or enhance processes leading to the obstruction of blood flow and ultimately to cardiovascular event like a heart attack.
Genetic Alzheimer’s Risk Discovery (GARD™)
A genetic test for multiple genetic polymorphisms (variants) associated with increased risk of the most common form of dementia: late-onset Alzheimer’s disease. GARD™ combines genetic assessment of genetic polymorphism for several key genes: apoliprotein E (ApoE), interleukin-10 (IL-10) and interleukin-6 (IL-6) with additional genes being added as development progresses.
PRIMALEUKIN™: Broad Spectrum Anti-Infective Therapy
Commonly known as interleukin-22 (IL-22), has a unique position as a combined antibacterial, anti-fungal and antiviral agent, harnessing and amplifying the body’s own natural defense against, and recovery from infection and as such has a potential to be targeted against several indications and commanding large market and multiple licensing opportunities. Granted patent has claims protection against all infections in most territories.
A ‘disruptive’ technology to engineer a sensor using a mathematically modeled ‘fractal dactyl’ surface with repeating patterns, millions of variants, creating topographically confined ‘cages’. Combined with a source signal (LED or electrical signal generating circuits), a novel device able to detect particles and pathogens sensing by ‘signature’ involving multiple (tens, hundreds or millions) of discrete points of proximity detection, dynamic or static, with advanced software analysis. Patent is granted in most territories.